A Phase 1 interventional study of Efinopegdutide and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive low dose efinopegdutide at a single dose on day 1
Drug: Efinopegdutide
Participants receive medium dose efinopegdutide at a single dose on day 1
Drug: Efinopegdutide
Participants receive high dose efinopegdutide at a single dose on day 1
Drug: Efinopegdutide
Participants receive multiple doses of efinopegdutide over 78 days
Drug: Efinopegdutide
Participants receive placebo to match efinopegdutide dose and regimen
Drug: Placebo
Subcutaneous injection
Also known as: MK-6024, HM12525A, JNJ-64565111,
placebo matching efinopegdutide
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 112 days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 78 days
Maximum Plasma Concentration (Cmax) of Efinopegdutide- single dose
Blood samples will be collected to determine the Cmax of efinopegdutide when administered as a single dose
Time frame: At designated time points up to 35 days
Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single dose
Blood samples will be collected to determine the Tmax of efinopegdutide when administered as a single dose
Time frame: At designated time points up to 35 days
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single dose
Blood samples will be collected to determine the AUC0-last of efinopegdutide when administered as a single dose
Time frame: At designated timepoints up to 35 days
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single dose
Blood samples will be collected to determine the AUC0-inf of efinopegdutide when administered as a single dose
Time frame: At designated timepoints up to 35 days
Terminal half life (t1/2) of Efinopegdutide- single dose
Blood samples will be collected to determine the t1/2 of efinopegdutide when administered as a single dose
Time frame: At designated timepoints up to 35 days
Apparent Clearance (CL) of Efinopegdutide- single dose
Blood samples will be collected to determine the CL of efinopegdutide when administered as a single dose
Time frame: At designated timepoints up to 35 days
Volume of Distribution (Vz) of Efinopegdutide- single dose
Blood samples will be collected to determine the Vz of efinopegdutide when administered as a single dose
Time frame: At designated timepoints up to 35 days
Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the Cmax of efinopegdutide when multiple doses are administered
Time frame: At designated time points up to 112 days
Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the Cmin of efinopegdutide when multiple doses are administered
Time frame: At designated time points up to 112 days
Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the Tmax of efinopegdutide when multiple doses are administered
Time frame: At designated time points up to 112 days
Terminal half life (t1/2) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the t1/2 of efinopegdutide when multiple doses are administered
Time frame: At designated timepoints up to 112 days
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple dose
Blood samples will be collected to determine the AUC0-last of efinopegdutide when multiple doses are administered
Time frame: At designated timepoints up to 112 days
Apparent Clearance (CL) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the CL of efinopegdutide when multiple doses are administered
Time frame: At designated timepoints up to 112 days
Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple dose
Blood samples will be collected to determine the Vss of efinopegdutide when multiple doses are administered
Time frame: At designated timepoints up to 112 days
Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple dose
Blood samples will be collected to determine the AUC0 to tau of efinopegdutide when multiple doses are administered
Time frame: At designated timepoints up to 78 days
Change from Baseline in Weight
Change from baseline in weight will be computed for participants who received multiple doses of efinopegdutide
Time frame: Baseline and day 112
Change from Baseline in HDL Cholesterol
Change from baseline in HDL cholesterol will be computed for participants who received multiple doses of efinopegdutide
Time frame: Baseline and day 112
Change from Baseline in LDL Cholesterol
Change from baseline in LDL cholesterol will be computed for participants who received multiple doses of efinopegdutide
Time frame: Baseline and day 112
Change from Baseline in Total Cholesterol
Change from baseline in total cholesterol will be computed for participants who received multiple doses of efinopegdutide
Time frame: Baseline and day 112
Change from Baseline in Triglycerides
Change from baseline in triglycerides will be computed for participants who received multiple doses of efinopegdutide
Time frame: Baseline and day 112
Number of participants with anti drug antibodies (ADA) to efinopegdutide
Blood samples will be collected to determine the number of participants with ADA to efinopegdutide
Time frame: At designated timepoints up to 112 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2022 to primary completion in Feb 2023, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide